RESUMEN
Fetal hemoglobin (HbF) induction constitutes a valuable and validated approach to treat the symptoms of sickle cell disease (SCD). Here, we synthesized pomalidomide-nitric oxide (NO) donor derivatives (3a-f) and evaluated their suitability as novel HbF inducers. All compounds demonstrated different capacities of releasing NO, ranging 0.3-30.3%. Compound 3d was the most effective HbF inducer for CD34+ cells, exhibiting an effect similar to that of hydroxyurea. We investigated the mode of action of compound 3d for HbF induction by studying the in vitro alterations in the levels of transcription factors (BCL11A, IKAROS, and LRF), inhibition of histone deacetylase enzymes (HDAC-1 and HDAC-2), and measurement of cGMP levels. Additionally, compound 3d exhibited a potent anti-inflammatory effect similar to that of pomalidomide by reducing the TNF-α levels in human mononuclear cells treated with lipopolysaccharides up to 58.6%. Chemical hydrolysis studies revealed that compound 3d was stable at pH 7.4 up to 24 h. These results suggest that compound 3d is a novel HbF inducer prototype with the potential to treat SCD symptoms.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Talidomida/análogos & derivados , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Relación Estructura-Actividad , Talidomida/síntesis química , Talidomida/química , Talidomida/uso terapéuticoRESUMEN
Thiazole, thiosemicarbazone and semicarbazone moieties are privileged scaffolds (acting as primary pharmacophores) in many compounds that are useful to treat several diseases, mainly tropical infectious diseases. In this review article, we critically analyzed the contribution of these scaffolds to medicinal chemistry in the last five years, focusing on tropical infectious diseases, such as Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. We also present perspectives for their use in drug design in order to contribute to the development of new drugs.
Asunto(s)
Infecciones por Protozoos/tratamiento farmacológico , Semicarbazonas/uso terapéutico , Tiazoles/uso terapéutico , Tiosemicarbazonas/uso terapéutico , Animales , Enfermedad de Chagas/tratamiento farmacológico , Diseño de Fármacos , Humanos , Leishmaniasis/tratamiento farmacológico , Malaria/tratamiento farmacológico , Tripanosomiasis Africana/tratamiento farmacológicoRESUMEN
Chagas disease, also known as American trypanosomiasis, is one of the 17 neglected tropical diseases (NTDs) according to World Health Organization. It is estimated that 8-10 million people are infected worldwide, mainly in Latin America. Chagas disease is caused by the parasite Trypanosoma cruzi and is characterized by two phases: acute and chronic. The current therapy for Chagas disease is limited to drugs such as nifurtimox and benznidazole, which are effective in treating only the acute phase of the disease. In addition, several side effects ranging from hypersensitivity to bone marrow depression and peripheral polyneuropathy have been associated with these drugs. Therefore, the current challenge is to find new effective and safe drugs against this NTD. The aim of this review is to describe the advances in the medicinal chemistry of new anti-chagasic compounds reported in the literature in the last five years. We report promising prototypes for drug discovery identified through target-based and phenotype-based strategies and present some important targets for the development of new synthetic compounds.
Asunto(s)
Enfermedad de Chagas/tratamiento farmacológico , Descubrimiento de Drogas , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Animales , Química Farmacéutica , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Relación Estructura-Actividad , Tripanocidas/químicaRESUMEN
N-oxide derivatives 5(a-b), 8(a-b), and 11(a-c) were designed, synthesized and evaluated in vitro and in vivo as potential drugs that are able to ameliorate sickle cell disease (SCD) symptoms. All of the compounds demonstrated the capacity to releasing nitric oxide at different levels ranging from 0.8 to 30.1%, in vivo analgesic activity and ability to reduce TNF-α levels in the supernatants of monocyte cultures. The most active compound (8b) protected 50.1% against acetic acid-induced abdominal constrictions, while dipyrone, which was used as a control only protected 35%. Compounds 8a and 8b inhibited ADP-induced platelet aggregation by 84% and 76.1%, respectively. Both compounds increased γ-globin in K562â¯cells at 100⯵M. The mechanisms involved in the γ-globin increase are related to the acetylation of histones H3 and H4 that is induced by these compounds. In vitro, the most promising compound (8b) was not cytotoxic, mutagenic and genotoxic.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Descubrimiento de Drogas , Histonas/metabolismo , Oxadiazoles/farmacología , gamma-Globinas/biosíntesis , Ácido Acético/antagonistas & inhibidores , Ácido Acético/farmacología , Acetilación , Anemia de Células Falciformes/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Células K562 , Estructura Molecular , Óxido Nítrico/metabolismo , Oxadiazoles/síntesis química , Oxadiazoles/química , Relación Estructura-ActividadRESUMEN
Dextran-coated poly (n-butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared and were evaluated for enhanced delivery of a promising anti-Leishmania drug candidate, hydroxymethylnitrofurazone (NFOH), to phagocytic cells. Currently available chemotherapy for leishmaniasis, such as pentavalent antimonials, presents low safety and efficacy. Furthermore, widespread drug resistance in leishmaniasis is rapidly emerging. To overcome these drawbacks, the use of nanosized delivery systems can reduce systemic drug toxicity and increase the drug concentration in infected macrophages, therefore improving treatment of leishmaniasis. PBCA-NPs containing NFOH (PBCA-NFOH-NPs) were prepared by an anionic emulsion polymerisation method. The z-average and polydispersity index (PDI) were determined by photon correlation spectroscopy, the zeta potential by microelectrophoresis and the entrapment efficiency by HPLC. Cytotoxicity was determined using macrophages from BALB/c mice. Efficacy tests were performed using Leishmania amazonensis promastigotes and amastigotes. The z-average of PBCA-NFOH-NPs was 151.5 ± 61.97 nm, with a PDI of 0.104 ± 0.01, a zeta potential of -10.1 ± 6.49 mV and an entrapment efficiency of 64.47 ± 0.43%. Efficacy in amastigotes revealed IC50 values of 0.33 µM and 31.2 µM for the nanostructured and free NFOH, respectively (95-fold increase). The cytotoxicity study indicated low toxicity of the PBCA-NFOH-NPs to macrophages. The selectivity index was 370.6, which is 49-fold higher than free NFOH (7.6). Such findings indicated that improved efficacy could be due to NP internalisation following site-specific drug delivery and reactivation of immune protective reactions by the NP components. Thus, PBCA-NFOH-NPs have the potential to significantly improve the treatment of leishmaniasis, with reduced systemic side effects.
Asunto(s)
Antiprotozoarios/metabolismo , Leishmania/efectos de los fármacos , Macrófagos/parasitología , Nanopartículas/metabolismo , Nitrofurazona/análogos & derivados , Animales , Supervivencia Celular/efectos de los fármacos , Concentración 50 Inhibidora , Macrófagos/fisiología , Ratones Endogámicos BALB C , Nanopartículas/toxicidad , Nitrofurazona/metabolismo , Pruebas de Sensibilidad ParasitariaRESUMEN
Tuberculosis (TB) remains a serious health problem responsible to cause millions of deaths annually. The scenario becomes alarming when it is evaluated that the number of new drugs does not increase proportionally to the emergence of resistance to the current therapy. Furoxan derivatives, known as nitric oxide (NO) donors, have been described to exhibit antitubercular activity. Herein, a novel series of hybrid furoxan derivatives (1,2,5-oxadiazole 2-N-oxide) (compounds 4a-c, 8a-c and 14a-c) were designed, synthesized and evaluated in vitro against Mycobacterium tuberculosis (MTB) H37Rv (ATCC 27294) and a clinical isolate MDR-TB strain. The furoxan derivatives have exhibited MIC90 values ranging from 1.03 to 62 µM (H37Rv) and 7.0-50.0 µM (MDR-TB). For the most active compounds (8c, 14a, 14b and 14c) the selectivity index ranged from 3.78 to 52.74 (MRC-5 cells) and 1.25-34.78 (J774A.1 cells). In addition, it was characterized for those compounds logPo/w values between 2.1 and 2.9. All compounds were able to release NO at levels ranging from 0.16 to 44.23%. Among the series, the phenylsulfonyl furoxan derivatives (compounds 14a-c) were the best NO-donor with the lowest MIC90 values. The most active compound (14c) was also stable at different pHs (5.0 and 7.4). In conclusion, furoxan derivatives were identified as new promising compounds useful to treat tuberculosis.
Asunto(s)
Antituberculosos/síntesis química , Antituberculosos/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Oxadiazoles/síntesis química , Oxadiazoles/farmacología , Antituberculosos/química , Antituberculosos/toxicidad , Línea Celular Tumoral , Técnicas de Química Sintética , Diseño de Fármacos , Humanos , Oxadiazoles/química , Oxadiazoles/toxicidadRESUMEN
Thrombosis is the main outcome of many cardiovascular diseases. Current treatments to prevent thrombotic events involve the long-term use of antiplatelet drugs. However, this therapy has several limitations, thereby justifying the development of new drugs. A series of N-oxide derivatives (furoxan and benzofuroxan) were synthesized and characterized as potential antiplatelet/antithrombotic compounds. All compounds (3a,b, 4a,b, 8a,b, 9a,b, 13a,b and 14a,b) inhibited platelet aggregation induced by adenosine-5-diphosphate, collagen, and arachidonic acid. All compounds protected mice from pulmonary thromboembolism induced by a mixture of collagen and epinephrine; however, benzofuroxan derivatives (13a,b and 14a,b) were the most active compounds, reducing thromboembolic events by up to 80%. N-oxide derivative 14a did not induce genotoxicity in vivo. In conclusion, 14a has emerged as a new antiplatelet/antithrombotic prototype useful for the prevention of atherothrombotic events.
Asunto(s)
Benzoxazoles/síntesis química , Benzoxazoles/farmacología , Oxadiazoles/síntesis química , Oxadiazoles/farmacología , Inhibidores de Agregación Plaquetaria/síntesis química , Embolia Pulmonar/prevención & control , Animales , Benzoxazoles/química , Colágeno/efectos adversos , Modelos Animales de Enfermedad , Epinefrina/efectos adversos , Humanos , Ratones , Simulación del Acoplamiento Molecular , Estructura Molecular , Oxadiazoles/química , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/farmacología , Embolia Pulmonar/inducido químicamenteRESUMEN
Prodrug design is a widely known molecular modification strategy that aims to optimize the physicochemical and pharmacological properties of drugs to improve their solubility and pharmacokinetic features and decrease their toxicity. A lack of solubility is one of the main obstacles to drug development. This review aims to describe recent advances in the improvement of solubility via the prodrug approach. The main chemical carriers and examples of successful strategies will be discussed, highlighting the advances of this field in the last ten years.
Asunto(s)
Profármacos/síntesis química , Profármacos/farmacología , Disponibilidad Biológica , Sistemas de Liberación de Medicamentos , Diseño de Fármacos , Profármacos/química , SolubilidadRESUMEN
We synthesized a series of novel dapsone-thalidomide hybrids (3a-i) by molecular hybridization and evaluated their potential for the treatment of type 2 leprosy reactions. All of the compounds had analgesic properties. Compounds 3c and 3h were the most active antinociceptive compounds and reduced acetic acid-induced abdominal constrictions by 49.8% and 39.1%, respectively. The hybrid compounds also reduced tumor necrosis factor-α levels in lipopolysaccharide-stimulated L929 cells. Compound 3i was the most active compound; at concentrations of 15.62 and 125 µM, compound 3i decreased tumor necrosis factor-α levels by 86.33% and 87.80%, respectively. In nude mice infected with Mycobacterium leprae in vivo, compound 3i did not reduce the number of bacilli compared with controls. Compound 3i did not have mutagenic effects in Salmonella typhimurium strains TA100 and TA102, with or without metabolic activation (S9 mixture). Our results indicate that compound 3i is a novel lead compound for the treatment of type 2 leprosy reactions.
Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , Dapsona/farmacología , Lepra/tratamiento farmacológico , Mycobacterium leprae/efectos de los fármacos , Talidomida/farmacología , Animales , Antibacterianos/química , Línea Celular , Dapsona/química , Relación Dosis-Respuesta a Droga , Humanos , Ratones , Ratones Desnudos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Relación Estructura-Actividad , Talidomida/químicaRESUMEN
Chronic ultraviolet (UV) radiation exposure is a major cause of skin cancer. A novel series of hybrid derivatives (I-VIII) for use in sunscreen formulations were synthesized by molecular hybridization of t-resveratrol, avobenzone, and octyl methoxycinnamate, and were characterized. The antioxidant activity values for VIII were comparable than to those of t-resveratrol. Compounds I-III and VI demonstrated Sun Protector Factor superior to that of t-resveratrol. Compounds I and IV-VIII were identified as new, broad-spectrum UVA filters while II-III were UVB filters. In conclusion, novel hybrid derivatives with antioxidant effects have emerged as novel photoprotective agents for the prevention of skin cancer.
Asunto(s)
Antioxidantes/síntesis química , Protectores Solares/síntesis química , Antioxidantes/química , Cinamatos/química , Humanos , Propiofenonas/química , Resveratrol , Neoplasias Cutáneas/prevención & control , Estilbenos/química , Factor de Protección Solar , Protectores Solares/química , Rayos UltravioletaRESUMEN
A series of anti-inflammatory derivatives containing an N-acyl hydrazone subunit (4a-e) were synthesized and characterized. Docking studies were performed that suggest that compounds 4a-e bind to cyclooxygenase (COX)-1 and COX-2 isoforms, but with higher affinity for COX-2. The compounds display similar anti-inflammatory activities in vivo, although compound 4c is the most effective compound for inhibiting rat paw edema, with a reduction in the extent of inflammation of 35.9% and 52.8% at 2 and 4 h, respectively. The anti-inflammatory activity of N-acyl hydrazone derivatives was inferior to their respective parent drugs, except for compound 4c after 5 h. Ulcerogenic studies revealed that compounds 4a-e are less gastrotoxic than the respective parent drug. Compounds 4b-e demonstrated mucosal damage comparable to celecoxib. The in vivo analgesic activities of the compounds are higher than the respective parent drug for compounds 4a-b and 4d-e. Compound 4a was more active than dipyrone in reducing acetic-acid-induced abdominal constrictions. Our results indicate that compounds 4a-e are anti-inflammatory and analgesic compounds with reduced gastrotoxicity compared to their respective parent non-steroidal anti-inflammatory drugs.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Ciclooxigenasa 1/metabolismo , Ciclooxigenasa 2/metabolismo , Hidrazonas/farmacología , Animales , Celecoxib , Inhibidores de la Ciclooxigenasa 2/farmacología , Diseño de Fármacos , Hemorragia Gastrointestinal/inducido químicamente , Hidrazonas/efectos adversos , Hidrazonas/química , Inflamación/tratamiento farmacológico , Masculino , Ratones , Modelos Moleculares , Simulación del Acoplamiento Molecular , Unión Proteica , Pirazoles/farmacología , Ratas , Ratas Wistar , Sulfonamidas/farmacologíaRESUMEN
Nonsteroidal anti-inflammatory drugs (NSAIDs) 1-5 containing an N-acyl hydrazone subunit were prepared and their antiplatelet and antithrombotic activities assessed in vitro and in vivo. Compounds 1-5 inhibited the platelet aggregation induced by adenosine diphosphate and/or arachidonic acid, with inhibition rates of 18.0%-61.1% and 65.9%-87.3%, respectively. Compounds 1 and 5 were the most active compounds, inhibiting adenosine-diphosphate-induced platelet aggregation by 57.2% and 61.1%, respectively. The inhibitory rates for arachidonic-acid-induced platelet aggregation were similar for compound 2 (80.8%) and acetylsalicylic acid (ASA, 80%). After their oral administration to mice, compounds 1, 3, and 5 showed shorter mean bleeding times than ASA. Compounds 1 and 5 also protected against thromboembolic events, with survival rates of 40% and 33%, respectively, compared with 30% for ASA. In conclusion, these results indicate that these novel NSAIDs containing an NAH subunit may offer better antiplatelet and antithrombotic activities than ASA.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Hidrazonas/administración & dosificación , Inhibidores de Agregación Plaquetaria/administración & dosificación , Agregación Plaquetaria/efectos de los fármacos , Animales , Ácido Araquidónico/toxicidad , Hemorragia/inducido químicamente , Hemorragia/tratamiento farmacológico , Hemorragia/patología , RatonesRESUMEN
We synthesized a series of novel dapsone-thalidomide hybrids (3a-i) by molecular hybridization and evaluated their potential for the treatment of type 2 leprosy reactions. All of the compounds had analgesic properties. Compounds 3c and 3h were the most active antinociceptive compounds and reduced acetic acid-induced abdominal constrictions by 49.8% and 39.1%, respectively. The hybrid compounds also reduced tumor necrosis factor-α levels in lipopolysaccharide-stimulated L929 cells. Compound 3i was the most active compound; at concentrations of 15.62 and 125 µM, compound 3i decreased tumor necrosis factor-α levels by 86.33% and 87.80%, respectively. In nude mice infected with Mycobacterium leprae in vivo, compound 3i did not reduce the number of bacilli compared with controls. Compound 3i did not have mutagenic effects in Salmonella typhimurium strains TA100 and TA102, with or without metabolic activation (S9 mixture). Our results indicate that compound 3i is a novel lead compound for the treatment of type 2 leprosy reactions.
Asunto(s)
Humanos , Animales , Ratones , Relación Estructura-Actividad , Talidomida/química , Estructura Molecular , Línea Celular , Dapsona/farmacología , Dapsona/química , Relación Dosis-Respuesta a Droga , Lepra/tratamiento farmacológico , Antibacterianos/síntesis química , Antibacterianos/farmacología , Antibacterianos/química , Mycobacterium leprae/efectos de los fármacosRESUMEN
Hydroxymethylnitrofurazone (NFOH) is a trypanocidal prodrug of nitrofurazone (NF), devoid of mutagenic toxicity. The purpose of this work was to study the chemical conversion of NFOH into NF in sodium acetate buffer (pH 1.2 and 7.4) and in human plasma and to determine preclinical pharmacokinetic parameters in rats. At pH 1.2, the NFOH was totally transformed into NF, the parent drug, after 48 h, while at pH 7.4, after the same period, the hydrolysis rate was 20%. In human plasma, 50% of NFOH was hydrolyzed after 24 h. In the investigation of kinetic disposition, the concentration of drug in serum versus time curve was used to calculate the pharmacokinetic parameters after a single-dose regimen. NFOH showed a time to maximum concentration of drug in serum (Tmax) as 1 h, suggesting faster absorption than NF (4 h). The most important results observed were the volume of distribution (V) of NFOH through the tissues, which showed a rate that is 20-fold higher (337.5 liters/kg of body weight) than that of NF (17.64 liters/kg), and the concentration of NF obtained by in vivo metabolism of NFOH, which was about four times lower (maximum concentration of drug in serum [Cmax] = 0.83 µg/ml; area under the concentration-time curve from 0 to 12 h [AUC0-12] = 5.683 µg/ml · h) than observed for administered NF (Cmax = 2.78 µg/ml; AUC0-12 = 54.49 µg/ml · h). These findings can explain the superior activity and lower toxicity of the prodrug NFOH in relation to its parent drug and confirm NFOH as a promising anti-Chagas' disease drug candidate.
Asunto(s)
Modelos Estadísticos , Nitrofurazona/análogos & derivados , Nitrofurazona/farmacocinética , Profármacos/farmacocinética , Tripanocidas/farmacocinética , Animales , Área Bajo la Curva , Tampones (Química) , Simulación por Computador , Humanos , Concentración de Iones de Hidrógeno , Hidrólisis , Masculino , Nitrofurazona/sangre , Nitrofurazona/química , Profármacos/química , Ratas , Ratas Wistar , Tripanocidas/sangre , Tripanocidas/químicaRESUMEN
Phthalimide derivatives containing furoxanyl subunits as nitric oxide (NO)-donors (3a-g) were designed, synthesized, and evaluated in vitro and in vivo for their potential uses in the oral treatment of sickle cell disease symptoms. All compounds (3a-g) demonstrated NO-donor properties at different levels. Moreover, compounds 3b and 3c demonstrated analgesic activity. Compound 3b was determined to be a promising drug candidate for the aforementioned uses, and it was further evaluated in K562 culture cells to determine its ability to increase levels of γ-globin expression. After 96 h at 5 µM, compound 3b was able to induce γ-globin expression by nearly three times. Mutagenic studies using micronucleus tests in peripheral blood cells of mice demonstrated that compound 3b reduces the mutagenic profile as compared with hydroxyurea. Compound 3b has emerged as a new leading drug candidate with multiple beneficial effects for the treatment of sickle cell disease symptoms and provides an alternative to hydroxyurea treatment.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Oxadiazoles/química , Oxadiazoles/farmacología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Donantes de Óxido Nítrico/síntesis química , Donantes de Óxido Nítrico/química , Donantes de Óxido Nítrico/farmacología , Donantes de Óxido Nítrico/uso terapéutico , Oxadiazoles/síntesis química , Oxadiazoles/uso terapéutico , Reacción en Cadena de la PolimerasaRESUMEN
Amino acids are well known to be an important class of compounds for the maintenance of body homeostasis and their deficit, even for the polar neuroactive aminoacids, can be controlled by supplementation. However, for the amino acid taurine (2-aminoethanesulfonic acid) this is not true. Due its special physicochemical properties, taurine is unable to cross the blood-brain barrier. In addition of injured taurine transport systems under pathological conditions, CNS supplementation of taurine is almost null. Taurine is a potent antioxidant and anti-inflammatory semi-essential amino acid extensively involved in neurological activities, acting as neurotrophic factor, binding to GABA A/glycine receptors and blocking the excitotoxicity glutamate-induced pathway leading to be a neuroprotective effect and neuromodulation. Taurine deficits have been implicated in several CNS diseases, such as Alzheimer's, Parkinson's, epilepsy and in the damage of retinal neurons. This review describes the CNS physiological functions of taurine and the development of new derivatives based on its structure useful in CNS disease treatment.
RESUMEN
In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.
Asunto(s)
Antiinfecciosos , Daño del ADN , Diseño de Fármacos , Nitrocompuestos , Profármacos , Animales , Antiinfecciosos/química , Antiinfecciosos/metabolismo , Antiinfecciosos/toxicidad , Fenómenos Químicos , Humanos , Metronidazol/química , Metronidazol/metabolismo , Metronidazol/toxicidad , Estructura Molecular , Nitrocompuestos/química , Nitrocompuestos/metabolismo , Nitrocompuestos/toxicidad , Nitrofurazona/química , Nitrofurazona/metabolismo , Nitrofurazona/toxicidad , Profármacos/química , Profármacos/metabolismo , Profármacos/toxicidad , Relación Estructura-ActividadRESUMEN
The compounds 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl nitrate (C1), (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl nitrate (C2), 3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C3), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (C4), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)benzyl nitrate (C5), and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]ethyl nitrate (C6) were evaluated with a micronucleus test using mouse peripheral blood to identify new candidate drugs for the treatment of sickle cell disease (SCD) that are safer than hydroxyurea. The compounds induced an average frequency of micronucleated reticulocytes (MNRET) of less than six per 1,000 cells at 12.5, 25, 50, and 100 mg/kg, whereas hydroxyurea induced an average MNRET frequency of 7.8, 9.8, 15, and 33.7 per 1000 cells respectively, at the same concentrations. Compounds C1-C6 are new non-genotoxic in vivo candidate drugs for the treatment of SCD symptoms.
Asunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Indoles/toxicidad , Animales , Femenino , Masculino , Ratones , Pruebas de Micronúcleos , Salmonella/genéticaRESUMEN
Chlorhexidine (CHX) remains one of the most effective and widely used antiplaque agents around the world, although its side effects still limit a long-term usage as the patient compliance for oral treatment with CHX. We hypothesize that a less water-soluble tetracation salt of CHX might be able to interact weakly with tooth enamel and oral taste cells, reducing those undesirable side effects of CHX. The chlorhexidine tetrapalmitate (CHXTP) was obtained and the antimicrobial activity was evaluated by hole-plate diffusion method and twofold tube dilution method; for measurement of its propensity to stain, we used the in vitro method of polymethylmethacrylate blocks in an infusion with black tea solution; the rate of its removal from oral cavity was studied by high-performance liquid chromatography measurement of CHX extracted from human saliva samples; and its effect on the human taste perception was evaluated by taste confusion matrix method. The results showed that CHXTP salt is very active against Streptococcus mutans, with no interference on taste perception and a low tendency to stain; however, chlorhexidine digluconate shows a better retention in saliva. The use of polyvinylpyrrolidone turned possible a nonstaining and tasteless CHXTP formulation to linger in mouth.
Asunto(s)
Clorhexidina/química , Antisépticos Bucales/química , Adolescente , Adulto , Clorhexidina/efectos adversos , Clorhexidina/farmacocinética , Clorhexidina/farmacología , Cromatografía Líquida de Alta Presión , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Cinética , Pruebas de Sensibilidad Microbiana , Antisépticos Bucales/efectos adversos , Antisépticos Bucales/farmacocinética , Antisépticos Bucales/farmacología , Saliva/química , Streptococcus mutans/efectos de los fármacos , Gusto , Percepción del Gusto , Decoloración de Dientes/inducido químicamente , Adulto JovenRESUMEN
The design of new drugs with better physiochemical properties, adequate absorption, distribution, metabolism, and excretion, effective pharmacologic potency and lacking toxicity remains is a challenge. Inflammation is the initial trigger of several different diseases, such as Alzheimer's disease, asthma, atherosclerosis, colitis, rheumatoid arthritis, depression, cancer; and disorders such as obesity and sexual dysfunction. Although inflammation is not the direct cause of these disorders, inflammatory processes often increase related pain and suffering. New anti-inflammatory drugs developed using molecular hybridization techniques to obtain multiple-ligand drugs can act at one or multiple targets, allowing for synergic action and minimizing toxicity. This work is a review of new anti-inflammatory drugs developed using the molecular modification approach.